PO.CL12.03 · 临床研究

黏液性乳腺癌的表观遗传和转录驱动因素

Epigenetic and transcriptional drivers of mucinous breast carcinoma

海报缩略图:黏液性乳腺癌的表观遗传和转录驱动因素
编号 5296 展板 16 时间 4/21 09:00–12:00 区域 Section 44 主讲 Lorenzo Ferrando
分会场 Epigenetics, Cytogenetics, and Clinical Molecular Genetics
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Lorenzo Ferrando1, Higinio Dopeso2, Laxmi Gusain2, Edaise M da Silva2, Thais Basili de Oliveira2, Lounes Djerroudi3, Hannah Y. Wen2, Hong Zhang2, Edi Brogi2, Richard P. Koche4, Pierre-Jacques Hamard4, Larry Norton5, Jorge S. Reis-Filho2, Britta Weigelt2, Fresia Pareja2

1Department of Internal Medicine, University of Genoa, Genoa, Italy,2Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY,3Deparment of Pathology, Curie Institute, Paris, France,4Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY,5Department of Medicine, Breast Service, Memorial Sloan Kettering Cancer Center, New York, NY

摘要 Abstract

中文摘要
背景:黏液性乳腺癌(MucBC)是雌激素受体(ER)阳性/HER2阴性乳腺癌(BC)中一种少见的组织学亚型,其特征为肿瘤细胞漂浮在黏蛋白池中。与ER阳性/HER2阴性的非特殊型浸润性导管癌(IDC-NST)相比,MucBCs携带较少的PIK3CA突变,且通常缺乏并发的1q获得/16q缺失。然而,尚未鉴定出可解释其黏液表型的特征性遗传改变。在此,我们试图确定MucBCs是否可能由独特的表观遗传改变驱动。 方法:我们使用全基因组DNA甲基化谱分析(n=40)和/或RNA测序(n=27)分析了40例纯MucBCs。我们评估了DNA甲基化年龄、表观遗传有丝分裂评分和整合的甲基化-转录组谱,将MucBCs与来自癌症基因组图谱(TCGA)中缺乏PIK3CA突变及并发1q获得/16q缺失的IDC-NSTs进行比较,以最小化遗传混杂因素。IDC-NSTs按绝经状态、ER/HER2状态和组织学分级以1:1比例匹配。使用ER阳性/HER2阴性的CAMA1、ZR-75-1和MCF7乳腺癌细胞系来研究候选通路和转录组变化。 结果:与匹配的IDC-NSTs相比,MucBCs表现出相对于患者实际年龄加速的DNA甲基化年龄(p=0.015),提示表观遗传失调,较低的表观遗传有丝分裂评分(p=0.0071),以及显著的全局增强子低甲基化(p<0.001)。整合的甲基化-转录组分析将ZBTB20和ZNF133鉴定为MucBCs中的关键转录调节因子(FDR<0.05),以及TGF-beta和雌激素反应通路的显著失调(FDR<0.05)。在CAMA1和ZR-75-1 BC细胞中,药理学抑制TGF-beta通路导致黏蛋白编码基因(MUC2、MUC20、MUCL1、MUC5B)表达增加,而沉默ZBTB20或ZNF133导致黏蛋白基因表达降低。在MCF7细胞中,过表达ZBTB20或ZNF133同样导致黏蛋白编码基因上调,并诱导TGF-beta通路的转录变化,包括TGFBR1、TGFB1、SMAD3和TRIM33(TIF1gamma)的下调以及ID1的上调,反映了在MucBCs中观察到的模式。 结论:MucBC表现出加速的DNA甲基化年龄和广泛的增强子低甲基化,凸显了深刻的表观基因组失调。关键转录因子,包括ZBTB20和ZNF133,似乎协调黏蛋白基因表达以及TGF-beta通路重编程,从而促成MucBC的黏液表型。
查看英文原文 English abstract
Background: Mucinous breast cancer (MucBC) is an uncommon histologic subtype of estrogen receptor (ER)-positive/HER2-negative breast cancer (BC) characterized by tumor cells floating in pools of mucin. In contrast to ER-positive/HER2-negative invasive ductal carcinoma of no special type (IDC-NST), MucBCs harbor fewer PIK3CA mutations and typically lack concurrent 1q gains/16q losses. Yet, no pathognomonic genetic alterations have been identified to explain their mucinous phenotype. Here, we sought to determine whether MucBCs might be driven by distinctive epigenetic alterations. Methods: We analyzed 40 pure MucBCs using genome-wide DNA methylation profiling (n=40) and/or RNA-sequencing (n=27). We evaluated DNA methylation age, epigenetic mitotic score, and integrated methylation-transcriptomic profiles, comparing MucBCs with IDC-NSTs from The Cancer Genome Atlas (TCGA) lacking PIK3CA mutations and concurrent 1q gains/16q losses to minimize genetic confounding factors. IDC-NSTs were matched at a 1:1 ratio by menopausal status, ER/HER2 status and histologic grade. The ER-positive/HER2-negative CAMA1, ZR-75-1 and MCF7 breast cancer cell lines were used to interrogate candidate pathways and transcriptomic changes. Results: Compared to matched IDC-NSTs, MucBCs exhibited accelerated DNA methylation age relative to patient chronological age (p=0.015), indicative of epigenetic dysregulation, lower epigenetic mitotic scores (p=0.0071), and pronounced global enhancer hypomethylation (p< 0.001). Integrated methylation-transcriptome analyses identified ZBTB20 and ZNF133 as key transcriptional regulators in MucBCs (FDR < 0.05), as well as significant dysregulation of the TGF-beta and estrogen-response pathways (FDR<0.05). In CAMA1 and ZR-75-1 BC cells, pharmacologic inhibition of the TGF-beta pathway led to increased expression of mucin-encoding genes ( MUC2 , MUC20 , MUCL1 , MUC5B ), while silencing of ZBTB20 or ZNF133 resulted in reduced mucin gene expression. In MCF7 cells, overexpression of ZBTB20 or ZNF133 similarly resulted in upregulation of mucin encoding genes and induced transcriptional changes in the TGF-beta pathway, including downregulation of TGFBR1, TGFB1, SMAD3 and TRIM33 ( TIF1gamma ) and upregulation of ID1, mirroring patterns observed in MucBCs. Conclusions: MucBC display accelerated DNA methylation age and widespread enhancer hypomethylation, underscoring profound epigenomic dysregulation. Key transcription factors, including ZBTB20 and ZNF133 , appear to orchestrate mucin gene expression as well as TGF-beta pathway reprogramming, contributing to the mucinous phenotype of MucBC.
利益披露 Disclosure
L. Ferrando, None.. H. Dopeso, None.. L. Gusain, None.. E. da Silva, None.. T. Basili de Oliveira, None.. L. Djerroudi, None.. H. Y. Wen, None.. H. Zhang, None.. E. Brogi, None.. R. P. Koche, None.. P. Hamard, None.. L. Norton, None. J. S. Reis-Filho, AstraZeneca Employment. B. Weigelt, Repare Therapeutics ). SAGA Diagnostics ). AstraZeneca Other, Immediate family member employed by AstraZeneca. F. Pareja, AstraZeneca Other, consulting. MultiplexDx Other, consulting.

← 返回 AACR 2026 检索